As Managing Partner of Tin Alley Ventures, Dr Andrew McLean is following his passion for supporting entrepreneurs on the courageous journey of company-building to solve generational human & global challenges. As part of the founding team at Oxford Science Enterprises (UK), he led investments into DJS Antibodies (acquired by Abbvie), Mirobio (acquired by Gilead), Vaccitech (inventor of the Oxford-AZ covid vaccine) and PepGen. He studied medicine at UWA and philosophy, politics, and economics at Oxford.